Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

virtualization

- PMLiVE

Cancer drug spend tops $100bn in 2014

But payers are starting to bulk at increasing prices

- PMLiVE

Eylea growth closes the gap with Lucentis

Bayer/Regeneron’s drug eye disease drug set for blockbuster status

Roche Basel Switzerland

Roche maintains top place in biologic sales

But the looming threat of biosimilars is set to shake up the market

Roche Basel Switzerland

Roche adds kidney cancer to anti-PD-L1 programme

Inhibitor already indicated for lung, bladder and breast cancer

- PMLiVE

AstraZeneca and PatientsLikeMe team up on real-world data

Two groups hoping to harness the power of the patient forum network

Roche Basel Switzerland

Trials of Roche’s new blindness candidate now underway

Lampalizumab in phase III for age-related maculardegeneration

- PMLiVE

Avastin approved for cervical cancer in EU

Was approved for the same indication in the US last summer

- PMLiVE

Amgen gets EU nod for wider use of Vectibix

US biotech’s cancer therapy can now be used in a first-line setting

- PMLiVE

The BMJ weighs in on Avastin/Lucentis debate

The UK’s leading medical journal says Avastin should be used for wet AMD to cut costs

- PMLiVE

Open health data network launches in US

'Open Humans’ wants people to share health information to accelerate medical breakthroughs

Evolution of the wearable tech revolution

Stuart Goodman delves into the world of wearables, further analysing what role they play in pharma’s future.

Blue Latitude Health

- PMLiVE

Not all data is created equal

Aurélie Pols from Mind Your Privacy has written this guest blog post on data privacy and security, and specifically the risks of HIPAA or PII non-compliance, in both the USA...

Blue Latitude Health

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links